Common name
difluoromethane
IUPAC name
difluoromethane
SMILES
FCF
Common name
difluoromethane
IUPAC name
difluoromethane
SMILES
FCF
INCHI
InChI=1S/CH2F2/c2-1-3/h1H2
FORMULA
CH2F2
Common name
difluoromethane
IUPAC name
difluoromethane
Molecular weight
52.023
clogP
1.258
clogS
-0.641
Frequency
0.0151
HBond Acceptor
0
HBond Donor
0
Total PolarSurface Area
0
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00101 | Pantoprazole |
|
Anti-Ulcer Agents; Proton Pump Inhibitors; Alimentary Tract and Metabolism; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs for Acid Related Disorders; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP3A4 Inhibitors; | Short-term (up to 16 weeks) treatment of erosive esophagitis. |
| FDBD00116 | Enflurane |
|
Anesthetics, Inhalation; Anesthetics; Nervous System; Halogenated Hydrocarbons; Anesthetics, General; CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); | Used for the induction and maintenance of general anaesthesia during surgery and cesarean section and also used for analgesia during vaginal delivery. |
| FDBD00423 | Perflutren |
|
Contrast Media; | Used as an ultrasound contrast imaging in cardiology and radiology. |
| FDBD00617 | Isoflurane |
|
Anesthetics, Inhalation; Anesthetics; Nervous System; Halogenated Hydrocarbons; Anesthetics, General; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); | For induction and maintenance of general anesthesia. |
| FDBD00802 | Fulvestrant |
|
Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Antagonists; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; Anti-Estrogens; CYP3A4 Inhibitors; Estrogen Receptor Antagonists; | For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. |
| FDBD00881 | Methoxyflurane |
|
Anesthetics, Inhalation; Analgesics; Nervous System; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2A6 Inhibitors; CYP2A6 Inhibitors (strong); CYP2A6 Inhibitors (moderate); CYP2A6 Inducers; CYP2A6 Inducers (strong); CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); CYP3A4 Inhibitors; | For use in the induction and maintenance of general anesthesia. |
| FDBD00898 | Lubiprostone |
|
Laxatives; Alimentary Tract and Metabolism; Drugs for Constipation; Chloride Channel Agonists; | For the treatment of chronic idiopathic constipation in the adult population. Also used for the treatment of irritable bowel syndrome with constipation in women who are 18 years of age or older. |
| FDBD01035 | Desflurane |
|
Anesthetics, Inhalation; Anesthetics; Nervous System; Halogenated Hydrocarbons; Anesthetics, General; | For use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults. |
| FDBD01279 | Roflumilast |
|
Respiratory System; Drugs for Obstructive Airway Diseases; | Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. |
| FDBD01396 | Eflornithine |
|
Antineoplastic Agents; Enzyme Inhibitors; Antiprotozoal Agents; Trypanocidal Agents; Dermatologicals; Antiparasitic Products, Insecticides and Repellents; Agents Against Leishmaniasis and Trypanosomiasis; Ornithine Decarboxylase Inhibitors; | Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth). |
44 ,
5
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 2gh6_ligand_frag_9.mol2 | 2gh6 | 1 | -5.41 | C(F)(F)F | 4 |
| 4m3d_ligand_frag_8.mol2 | 4m3d | 1 | -5.38 | C(F)(F)F | 4 |
| 1ela_ligand_frag_1.mol2 | 1ela | 1 | -5.37 | C(F)(F)F | 4 |
| 1ele_ligand_frag_1.mol2 | 1ele | 1 | -5.37 | C(F)(F)F | 4 |
| 4m3b_ligand_frag_0.mol2 | 4m3b | 1 | -5.37 | FC(F)F | 4 |
| 4m3e_ligand_frag_0.mol2 | 4m3e | 1 | -5.37 | FC(F)F | 4 |
605 ,
61
